Skip to content
value.today

Nemus Bioscience, Inc.

🇺🇸 Costa Mesa, California, USAPharmaceuticalsFounded 2011

Formerly Load Guard Logistics, Inc., Load Guard Transportation, Inc.

Nemus Bioscience, Inc. is listed today as Skye Bioscience Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 8 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Nemus Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$40 MPrivate placement after listing$10 to $50 million

Nemus Bioscience, Inc.: Private sale, Mar 2024

Investors in this round

13 investors had bought by the notice of Mar 27, 2024: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,400,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Kaitlyn Arsenault · Executive Officer · Chief Financial Officer
  • Punit Dhillon · Executive Officer, Director · Chief Executive Officer, Chairman and Director
  • Andrew Schwab · Director
  • Annalisa Jenkins · Director
  • Deborah Charych · Director
  • Keith Ward · Director
  • Margaret Dalesandro · Director
  • Paul Grayson · Director
  • Praveen Tyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in all US states
  • Piper Sandler & Co (CRD 665) · Minneapolis, MinnesotaSold in all US states

Signed by Kaitlyn Arsenault, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 27, 2024. Read the notice at the SEC.

equitySEC
Jan 2024$50 MPrivate placement after listing$10 to $50 million

Nemus Bioscience, Inc.: Private sale, Jan 2024

Investors in this round

11 investors had bought by the notice of Feb 12, 2024: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,499,371
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Kaitlyn Arsenault · Executive Officer · Chief Financial Officer
  • Punit Dhillon · Executive Officer, Director · Chief Executive Officer, Chairman and Director
  • Andrew Schwab · Director
  • Deborah Charych · Director
  • Keith Ward · Director
  • Margaret Dalesandro · Director
  • Paul Grayson · Director
  • Praveen Tyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in all US states
  • Piper Sandler & Co (CRD 665) · Minneapolis, MinnesotaSold in all US states

Signed by Kaitlyn Arsenault, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 12, 2024. Read the notice at the SEC.

equity, optionsSEC
Aug 2023$62 MPrivate placement after listing$50 to $250 million

Nemus Bioscience, Inc.: Private sale, Aug 2023

Investors in this round

12 investors had bought by the notice of Aug 29, 2023: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$62 M of $62 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Kaitlyn Arsenault · Executive Officer · Chief Financial Officer
  • Punit Dhillon · Executive Officer, Director · Chief Executive Officer, Chairman and Director
  • Andrew Schwab · Director
  • Deborah Charych · Director
  • Keith Ward · Director
  • Margaret Dalesandro · Director
  • Paul Grayson · Director
  • Praveen Tyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “For a description of these transactions, see the Company's Current Report on Form 8-K, as filed with the SEC on August 21, 2023.”
  • On a merger: “"A portion of this offering is made pursuant to that certain Agreement and Plan of Merger and Reorganization, dated August 15, 2023, by and among Skye Bioscience, Inc., Aquila Merger Sub, Inc., and Bird Rock Bio, Inc. (the ""Merger Agreement"")."”

Signed by Kaitlyn Arsenault, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 29, 2023. Read the notice at the SEC.

equity, debt, optionsSEC
Nov 2018$2 MPrivate placement after listing$2 to $10 million

Nemus Bioscience, Inc.: Private sale, Nov 2018

Investors in this round

1 investor had bought by the notice of Nov 15, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $33 M offered; $31 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian S. Murphy · Executive Officer, Director
  • Douglas A. Cesario · Executive Officer
  • Avtar L. Dhillon · Director
  • James L. Heppell · Director
  • Punit S. Dhillon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $20MM of convertible debt and warrants to purchase 25MM shares of common stock. If warrants are exercised in full, the Issuer will receive aggregate gross proceeds of $12.5MM (included in Total Offering Amount and Total Remaining to be Sold).”

Signed by Douglas A. Cesario, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 15, 2018. Read the notice at the SEC.

equity, debt, optionsSEC
Jan 2018$4 MPrivate placement after listing$2 to $10 million

Nemus Bioscience, Inc.: Private sale, Jan 2018

Investors in this round

2 investors had bought by the notice of Feb 23, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $9 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian S. Murphy · Executive Officer, Director
  • Elizabeth M. Berecz · Executive Officer
  • James L. Heppell · Director
  • Punit S. Dhillon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “If the warrants are exercised in full, the company will receive aggregate gross proceeds of $4,420,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to be Sold.”

Signed by Elizabeth M. Berecz, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 23, 2018. Read the notice at the SEC.

equity, debt, optionsSEC
Nov 2017$2 MPrivate placement after listing$2 to $10 million

Nemus Bioscience, Inc.: Private sale, Nov 2017

Investors in this round

2 investors had bought by the notice of Nov 14, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian S. Murphy · Executive Officer, Director
  • Cosmas N. Lykos · Executive Officer, Director
  • Elizabeth M. Berecz · Executive Officer
  • Douglas S. Ingram · Director
  • Gerald W. McLaughlin · Director
  • Thomas A. George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “For general corporate purposes, including, without limitation, to pay down obligations and other working capital items.”

Signed by Elizabeth M. Berecz, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2017. Read the notice at the SEC.

equitySEC
Jan 2017$1 MPrivate placement after listingUnder $2 million

Nemus Bioscience, Inc.: Private sale, Jan 2017

Investors in this round

5 investors had bought by the notice of Jan 13, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian S. Murphy · Executive Officer
  • Cosmas N. Lykos · Executive Officer, Director
  • Elizabeth M. Berecz · Executive Officer
  • Douglas S. Ingram · Director
  • Gerald W. McLaughlin · Director
  • Thomas A. George · Director
  • Francicso W. Mendez · Promoter · Former officer/director
  • Yosbani W. Mendez · Promoter · Former officer/director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in all US states

Remarks in the notice

  • On fees: “Sales Compensation - warrants to purchase 480,000 shares of common stock at an exercise price of $0.25 per share”
  • On the use of proceeds: “Issuer intends to use proceeds of the financing to fund advancement of its proprietary cannabinoid-based therapeutics and for gen. corp. purposes (includes payment of salaries to its exec. officers and other employees in the ordinary course of business)”

Signed by Elizabeth M. Berecz, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 13, 2017. Read the notice at the SEC.

equitySEC
Aug 2015$5 MPrivate placement after listing$2 to $10 million

Nemus Bioscience, Inc.: Private sale, Aug 2015

Investors in this round

15 investors had bought by the notice of Aug 27, 2015: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$213,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian S. Murphy · Executive Officer
  • Cosmas N. Lykos · Executive Officer, Director
  • Douglas S. Ingram · Executive Officer, Director
  • Elizabeth M. Berecz · Executive Officer
  • Gerald W. McLaughlin · Director
  • Thomas A. George · Director
  • Francicso W. Mendez · Promoter · Former officer/director
  • Yosbani W. Mendez · Promoter · Former officer/director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Midtown Partners & Co., LLC (CRD 104223) · New York, New YorkSold in CA, FL, NJ, NY

Remarks in the notice

  • On fees: “Additional Sales Compensation-warrants to purchase 187,500 shares of common stock.”
  • On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payment of salaries to its executive officers and other employees in the ordinary course of business.”

Signed by Elizabeth Berecz, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 27, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Nemus Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2024

That is all the official record says: Nemus Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Nemus Bioscience, Inc. are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Nemus Bioscience, Inc.
InvestorKindAmountRoundRoleSource
Douglas S. IngramPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2015)SEC Form 3
Emerald Health Sciences Inc.Companynot statednot statedHeld Series B and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Skye Bioscience Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nemus Bioscience, Inc.
NameRoleNamed in
Kaitlyn ArsenaultChief Financial OfficerMar 2024
Punit DhillonChief Executive Officer, Chairman and DirectorMar 2024
Brian S. MurphyExecutive officerNov 2018
Douglas A. CesarioExecutive officerNov 2018
Elizabeth M. BereczExecutive officerFeb 2018
Cosmas N. LykosExecutive officerNov 2017
Douglas S. IngramExecutive officerAug 2015
Andrew SchwabDirectorMar 2024
Annalisa JenkinsDirectorMar 2024
Deborah CharychDirectorMar 2024
Keith WardDirectorMar 2024
Margaret DalesandroDirectorMar 2024
Paul GraysonDirectorMar 2024
Praveen TyleDirectorMar 2024
Punit DhillonChief Executive Officer, Chairman and DirectorMar 2024
Avtar L. DhillonDirectorNov 2018
Brian S. MurphyDirectorNov 2018
James L. HeppellDirectorNov 2018
Punit S. DhillonDirectorNov 2018
Jim S. HeppellDirectorJan 2018
Cosmas N. LykosDirectorNov 2017
Douglas S. IngramDirectorNov 2017
Gerald W. McLaughlinDirectorNov 2017
Thomas A. GeorgeDirectorNov 2017
Francicso W. MendezFormer officer/directorJan 2017
Yosbani W. MendezFormer officer/directorJan 2017

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.